Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VICTORIA trial of vericiguat in heart failure with reduced ejection fraction
NL-OMON47015Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in heart failure with reduced ejection fraction (HFrEF) comparing Vericiguat + standard of care with Placebo + standard of care (2 arms). Started Dec 2016; status: active, not recruiting.
02
Drugs
vericiguat
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NL-OMON47015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47015.